Drawing for AIGNOSTICS

USPTO serial 79343755

AIGNOSTICS

Reviewed by CopyMark Law Group

Reg. 7152936Status 700Registered
Filing date
Status date
Registration date
Sep 5, 2023
Examiner
MESSICK, TABITHA LEE
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with AIGNOSTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nicholas D. Wells

Nicholas D. Wells Legends Law Group, PLLC330 Main StKaysville, UT 84037UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
009Downloadable software for providing and facilitating medical diagnosis, for managing and analysing medical data, and for managing data and physician and patient communications related to clinical trials, and for managing data and communications of pharmaceutical, scientific, biological and clinical research, all of the foregoing for use in the fields of pathology, medical research, drug discovery and development, and artificial intelligence; downloadable software using artificial intelligence and machine learning for providing and facilitating medical research, medical diagnostics, medical treatments, clinical trials and pharmaceutical research; downloadable software for the integration of artificial intelligence and machine learning in the field of big dataACTIVE—
042Software development; research in the field of artificial intelligence technology; providing temporary use of online non-downloadable computer programs using artificial intelligence for the analysis of medical data; Software as a service (SAAS) featuring software for processing, diagnosing and analyzing medical data using machine learning algorithms and artificial intelligence; analysis of human tissues for medical research; analysis of human serum for medical research; medical and pharmacological research services; provision of information and data relating to medical research; clinical research in the fields of pathology, histology, oncology, and drug discovery and development; medical and scientific research, namely, conducting clinical trials for others; biological research, clinical research in the fields of pathology, histology, oncology, drug discovery, drug development and medical research; scientific research in the nature of conducting clinical trials for others for pharmaceutical productsACTIVE—
044Medical diagnostic testing services; medical analysis services for cancer diagnosis and prognosis; medical analysis services relating to the treatment of persons; medical analysis services for diagnostic and treatment purposes provided by medical laboratoriesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 2, 2024FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Dec 7, 2023FICSFINAL DISPOSITION NOTICE SENT TO IB—
Dec 7, 2023FIMPFINAL DISPOSITION PROCESSED—
Dec 5, 2023FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Sep 5, 2023NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Sep 5, 2023R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 20, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 20, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 19, 2023GPNXNOTIFICATION PROCESSED BY IB—
May 31, 2023OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
May 31, 2023OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
May 31, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 18, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 2, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 2, 2023RFNTREFUSAL PROCESSED BY IB—
May 1, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 1, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 6, 2023RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Apr 6, 2023RFRRREFUSAL PROCESSED BY MPU—
Feb 20, 2023RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 19, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 15, 2023DOCKASSIGNED TO EXAMINER—
Jul 5, 2022MAFRAPPLICATION FILING RECEIPT MAILED—
Jul 1, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 30, 2022REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance